• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Diabetic Peripheral Neuropathy - Pipeline Review, H2 2012 Product Image

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2012

  • ID: 2366319
  • December 2012
  • 43 pages
  • Global Markets Direct

Diabetic Peripheral Neuropathy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Diabetic Peripheral Neuropathy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy. Diabetic Peripheral Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Peripheral Neuropathy.
- A review of the Diabetic READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Diabetic Peripheral Neuropathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Diabetic Peripheral Neuropathy 7
Diabetic Peripheral Neuropathy Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Diabetic Peripheral Neuropathy Therapeutics – Products under Development by Companies 12
Companies Involved in Diabetic Peripheral Neuropathy Therapeutics Development 13
Daiichi Sankyo Company, Ltd 13
Sigma-Tau S.p.A. 14
Grunenthal GmbH 15
Creative Peptides Sweden AB 16
Viromed Co., Ltd. 17
Cebix Incorporated 18
Diabetic Peripheral Neuropathy – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
tapentadol ER - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
VM-202 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Proinsulin C-peptide (human) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
levocarnitine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DS-5565 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Ersatta - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Diabetic Peripheral Neuropathy Therapeutics – Drug Profile Updates 35
Diabetic Peripheral Neuropathy Therapeutics – Discontinued Products 37
Diabetic Peripheral Neuropathy Therapeutics - Dormant Products 38
Diabetic Peripheral Neuropathy – Product Development Milestones 39
Featured News & Press Releases 39
Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 39
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 39
May 04, 2012: Pfizer Reports Top-Line Results From Phase III Trial Of Lyrica Capsules CV In Patients With Diabetic Peripheral Neuropathy 40
Feb 21, 2012: SK Biopharmaceuticals Initiates Phase II Trials In US 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Diabetic Peripheral Neuropathy, H2 2012 7
Products under Development for Diabetic Peripheral Neuropathy – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Daiichi Sankyo Company, Ltd, H2 2012 13
Sigma-Tau S.p.A., H2 2012 14
Grunenthal GmbH, H2 2012 15
Creative Peptides Sweden AB, H2 2012 16
Viromed Co., Ltd., H2 2012 17
Cebix Incorporated, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Diabetic Peripheral Neuropathy Therapeutics – Drug Profile Updates 35
Diabetic Peripheral Neuropathy Therapeutics – Discontinued Products 37
Diabetic Peripheral Neuropathy Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2012 7
Products under Development for Diabetic Peripheral Neuropathy – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos